Wegovy’s New 7.2 mg Dose and ‘Skin Tingling’: A Chattanooga Physician Explains Dysesthesia
I’m an emergency and Family Medicine physician in Chattanooga, Tennessee, and founder of Summit Metabolic Health. I read every patient chart personally. These articles give honest, evidence-based answers about GLP-1 medications and metabolic health.
Wegovy’s New 7.2 mg Dose and “Skin Tingling”: A Chattanooga Physician Explains Dysesthesia
I am Dr. Paul Miranda, a board-certified physician at Summit Metabolic Health, and I read every patient chart myself. The new high-dose semaglutide is a genuine advance in weight loss — but it introduced a side effect the standard doses rarely caused, and the patients I worry about most are the ones who found out about it from a Reddit thread instead of a doctor. Let me give Tennessee the straight version.
What Is Wegovy 7.2 mg, and Why the New Dose?
The FDA approved semaglutide 7.2 mg — “Wegovy HD” — in March 2026, a step up from the previous 2.4 mg ceiling. In its trial (STEP UP), the high dose produced roughly 20.7 percent average body-weight loss over about 72 weeks, which pulls semaglutide up to rough parity with tirzepatide on weight loss (STEP UP trial; individual results vary). For a patient who has plateaued at the standard dose and needs more, that is a meaningful new option. But more medication came with a new, dose-dependent side effect.
Dysesthesia: The “Burning Skin” Sensation, Explained
Dysesthesia is the medical word for an abnormal skin sensation — tingling, burning, prickling, or numbness — that occurs without any injury to the skin itself. On the high dose of semaglutide it became notably more common. In the STEP UP trial, about one in five patients on the 7.2 mg dose reported dysesthesia, compared with far fewer on the standard 2.4 mg dose and almost none on placebo. It is real, it is new to this dose level, and — importantly — it is generally not dangerous.
This is not unique to semaglutide, either. Pharmacovigilance analysis has flagged dysesthesia as a dose-dependent, class-level signal across the higher-dose GLP-1 medications — it has shown up with high-dose tirzepatide and with the investigational triple-agonist retatrutide as well (VigiBase analysis, PMID 42168638). The common thread is dose: it clusters at the top of the range. That single fact is the key to managing it.
What to Actually Do About It — and Why It’s Reassuring
Here is the good news buried in the data. Because dysesthesia is dose-dependent, it is also, in most cases, dose-reversible. The typical sensation is mild to moderate, and when it is bothersome, stepping the dose back down usually settles it. The correct approach is the boring, careful one: complete the standard titration first, escalate to 7.2 mg deliberately, and step back if the trade-off is not worth it for that patient. What you should not do is “push through” an escalating neurological symptom on your own, or discover the side effect only after you have already jumped to the top dose.
Why This Should Be a Conversation Before You Escalate — Chattanooga
This is the part that matters most, and it is where physician-led care and a refill service part ways. The high dose is not automatically the “better” dose — it is more weight loss and a higher chance of this side effect, and whether that trade is worth it depends on the individual patient. That is a decision to make together, with informed consent, before the escalation — not something to reverse-engineer after a scary week.
A refill service that automatically maxes your dose has no incentive — and often no ability — to talk you through this before it happens, or to walk the dose back when it does. That flexibility is the whole point of physician-led care.
At Summit Metabolic Health, I bring up dysesthesia before anyone escalates to the high dose, and I can step the dose back down the moment it is not worth it. Software that scores a form and ships a maximum dose cannot do either. That is not a small difference — it is the difference between a side effect you were warned about and one that blindsided you. It is why I read every chart myself.
The Bottom Line for Chattanooga
Semaglutide 7.2 mg is a real step forward in weight loss, and dysesthesia is the price of admission that comes with it for some patients — a new, dose-dependent skin sensation that is usually mild, usually reversible, and entirely worth discussing before you move up. The medication is not the problem. Being escalated to the top dose without a word about what might come with it — that is the problem. In Tennessee, I make sure that conversation happens first.
On the high dose and unsure whether it’s right for you? Book a free 20-minute consultation with Dr. Miranda.
You can apply in about five minutes at summitmetabolichealth.com/apply. I personally review every application and reach out — no algorithms, no sales calls.